Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 13, 2023 17:00 ET
|
Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy...
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
October 18, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous...
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
October 02, 2023 12:53 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry...
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
September 21, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 14, 2023 16:15 ET
|
Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results...
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
July 31, 2023 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
July 27, 2023 07:00 ET
|
Checkpoint Therapeutics, Inc
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a...
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
June 28, 2023 08:00 ET
|
Checkpoint Therapeutics, Inc
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date...
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Checkpoint Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
April 27, 2020 07:00 ET
|
Fields Kupka & Shukurov LLP
NEW YORK, April 27, 2020 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Checkpoint Therapeutics,...